Zusammenfassung
Die interindividuelle Ansprechbarkeit auf eine neuroleptische Therapie unterliegt einer beträchtlichen Variation. Im Prinzip kommen dafür 3 Hauptursachen in Betracht: 1. pharmakokinetische Unterschiede, die zu deutlich verschiedenen Neuroleptikakonzentrationen bei Patienten führen, die mit gleicher Dosierung behandelt werden; 2. unterschiedliche Dosis-Wirkungs-Beziehungen auf Rezeptorebene, die auf genetische oder andere krankheitsbezogene Faktoren zurückgeführt werden können; 3. Unterschiede in der Patientencompliance.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Aaes-Jorgensen T, Kirk L, Petersen E, Danneskiold-Samsoe P, Jorgensen A (1983) Serum con-centrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo. Psychopharmacology 81: 68–72
Amdur MA (1979) Medication compliance in outpatient psychotherapy. Compr Psychiatry 20: 339–346
Aravagiri M, Hawes EM, Midha KK (1984) Radioimmunoassay for the sulfoxide metabolite of trifluoperazine and its application to a kinetic study in humans. J Pharm Sci 73: 1383–1387
Benitez J, Pinjas B, Garcia MA, Martinez C, Llerena A, Cobaleda J (1989) Debrisoquine oxidation phenotype in psychiatric patients. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York London Paris Tokyo Hongkong (Pharmacology series, vol 7 ), pp 206–216
Bressolle F, Bres J, Blanchin MD, Gomeni R (1984) Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. J Pharm Sci 73: 1128–1136
Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19: 435–442
Dahl SG (1981) Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacology 20: 1299–1302
Dahl SG (1986) Plasma level monitoring of antipsychotic drugs clinical utility. Clin Pharmacokinet 11: 36–61
Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448
Dahl SG, Strandjord RE, Sigfusson S (1977) Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol 11: 305–310
Dahl SG, Johnsen H, Lee CR (1982 a) Gas chromatographic mass spectrometric identification of O-demethylated and monohydroxylated metabolites of levomepromazine in blood from psychiatric patients by selected ion recording with high resolution. Biomed Mass Spectrom 9: 534–538
Dahl SG, Bratlid T, Lingjaerde O (1982 b) Plasma and erythrocyte levels of methotrimeprazine and two of its nonpolar metabolites in psychiatric patients. Ther Drug Monit 4: 81–87
Dahl SG, Kauffmann E, Mompon B, Purcell T (1987) Nuclear magnetic resonance analysis of methotrimeprazine (levomepromazine) hydroxylation in humans. J Pharm Sci 76: 541–544
Farde L, Wiesel F-A, Nilsson L, Sedvall G (1989) The potential of positron emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York London Paris Tokyo Hong Kong (Psychopharmacology series, vol 7 ), pp 32–39
Gravem A, Engstrand E, Guleng RJ (1978) Cis(z)-clopenthixol and clopenthixol ( Sordinol) in chronic psychotic patients. Acta Psychiatr Scand 58: 384–388
Hals P-A, Hall H, Dahl SG (1986) Phenothiazine drug metabolites: Dopamine D2 receptor, α1- and α2-adrenoceptor binding. Eur J Pharmacol 125: 373–381
Hals P-A, Hall H, Dahl SG (1988) Muscarinic cholinergic and histamine HI reeptor binding of phenothiazine drug metabolites. Life Sci 43: 405–412
Hulka BS, Cassel JC, Kupper LL (1976) Disparities between medications prescribed and consumed among chronic disease patients. In: Lasagna L (ed) Patient compliance. Futura, Mount Kisco, NY, pp 123–152
Johnsen H, Dahl SG (1982) Identification of O-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man. Drug Metab Dispos 10: 63–67
Jorgensen A (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis(Z)- flupentixol and intramuscular cis(Z)-flupentixol decanoate in viscoleo. Eur J Clin Pharmacol 18: 355–360
Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor & Francis, London, pp 111–174
Jorgensen A, Aaes-Jorgensen T (1988) Pharmacokinetic variations of zuclopenthixol and flupentixol administered orally or intramuscularly as retard or depot formulations. Nord Psychiatr Tidsskr 42: 501–502
Jorgensen A, Aaes-Jorgensen T, Gravem A, Amtor KF, Dencker SJ, Rosell I, Baastrup PC, Buckhave J, Gram LF (1985) Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology 87: 364–367
Larsson M, Axelsson R, Forsman A (1984) On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. Curr Ther Res 36: 1071–1088
Marder S, Hawes EM, Putten T van, Hubbard JW, McKay G, Mintz J, May PRA, Midha KK (1986) Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology 88: 480–483
Märtensson E, Nyberg G (1989) Active metabolites in plasma and CSF - Implications for therapeutic drug monitoring. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York London Paris Tokyo Hong Kong (Psychopharmacology series, vol 7 ), pp 257–268
Mendlewicz J, Linkowski P, Alexandre J, Schoutens A (1981) Haloperidol plasma levels and clinical response in schizophrenia. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry -Neuroleptic and antidepressant research. Macmillan, London, pp 233–237
Morel E, Lloyd KG, Dahl SG (1987) Anti-apomorphine effects of phenothiazine drug metabolites. Psychopharmacology 92: 68–72
Petersen PV, Moller Nielsen I, Pedersen V, Jorgensen A, Lassen N (1977) Thioxanthenes. In: Usdin E, Forrest IS (eds) Psychotherapeutic drugs, part 2: Applications. Dekker, New York, pp 827–867
Putten T van, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734
Usdin E (1971) The assay of chlorpromazine and metabolites in blood, urine and other tissues. CRC Grit Rev Clin Lab Sci 2: 347–391
Weiner PK, Langridge RL, Blaney JM, Schaefer R, Kollman PA (1982) Electrostatic potential molecular surfaces. Proc Natl Acad Sci USA 79: 3754–3758
Wiesel F-A, Alfredsson G, Ehrnebo M, Sedvall G (1980) The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 17: 385–391
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dahl, S.G. (1990). Pharmakokinetik der Neuroleptika. In: Müller-Oerlinghausen, B., Möller, HJ., Rüther, E. (eds) Thioxanthene. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75194-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-75194-3_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-51847-1
Online ISBN: 978-3-642-75194-3
eBook Packages: Springer Book Archive